Total trials
66
Active
5
Phase 3
1
Total enrollment
9,161
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Human albumin | — | — | — | — | — | 1 | |
| Sodium Hyaluronate 0.15% and Dexpanthenol 2% drops | — | — | — | — | — | 1 | |
| Sodium Hyaluronate 0.15% and Trehalose 3% drops | — | — | — | — | — | 1 | |
| Sodium Hyaluronate 0.2% and Amino acids drops | — | — | — | — | — | 1 |
Next readouts
- 2025-12-01
- 2026-12-31
Top conditions
- Presbyopia20
- Cataract15
- Refractive Errors9
- Low Vision6
- Keratoconus6
- Near Vision5
- Visual Acuity3
- Vision Disorders3
Frequently asked questions about Democritus University of Thrace
- How many clinical trials does Democritus University of Thrace have on ClinicalTrials.gov?
- Democritus University of Thrace is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Democritus University of Thrace's trials are in Phase 3?
- 1 of Democritus University of Thrace's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Democritus University of Thrace focus on?
- Democritus University of Thrace's most-studied conditions on ClinicalTrials.gov are Presbyopia, Cataract, Refractive Errors, Low Vision, Keratoconus.
- When are Democritus University of Thrace's next clinical trial readouts?
- Democritus University of Thrace has 2 upcoming primary-completion readouts tracked here; the soonest is “PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS”, expected around 2025-12-01.